- Cybin (CYBN) will initiate first-in-human dosing of its proprietary deuterated DMT (N,N-dimethyltryptamine) molecule, CYB004
- The Netherlands-based trial marks the first time a deuterated DMT molecule will be evaluated in humans
- The trial seeks to optimize the dosing and delivery of CYB004 as a potential treatment for generalized anxiety disorder
- Cybin is an ethical biopharmaceutical company developing psychedelic therapeutics to address mental health issues
- Cybin (CYBN) opened with a gain of 6 per cent, trading at $0.53 per share
Cybin (CYBN) will initiate the first-in-human dosing of its proprietary deuterated DMT molecule, CYB004.
The news follows approval from an independent ethics committee in the Netherlands to amend the company’s ongoing CYB004-E phase 1 trial, which is taking place in the country’s Centre for Human Drug Research.
The trial seeks to optimize the dosing and delivery of CYB004 as a potential treatment for generalized anxiety disorder.
This marks the first time a deuterated DMT molecule will be evaluated in humans and the largest ever phase 1 DMT trial conducted to date.
Based on preclinical studies, CYB004 has demonstrated an improved bioavailability, duration and pharmacokinetic profile compared to DMT when administered via intravenous and inhaled routes.
“With strong intellectual property in place and promising preclinical data, we believe we have a solid clinical development path forward for CYB004,” said Doug Drysdale, Cybin’s CEO.
The company will provide additional updates on its CYB004 program at its upcoming virtual R&D Day on February 28, 2023. Registration is now open.
Cybin is an ethical biopharmaceutical company developing psychedelic therapeutics to address mental health issues.
Cybin (CYBN) opened with a gain of 6 per cent, trading at $0.53 per share.
